Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
Human papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by the...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Journal of Biomedicine and Biotechnology |
Online Access: | http://dx.doi.org/10.1155/2011/272806 |
id |
doaj-f18e5f5ba1a44e9fbca74b9da4a915ff |
---|---|
record_format |
Article |
spelling |
doaj-f18e5f5ba1a44e9fbca74b9da4a915ff2020-11-25T01:35:45ZengHindawi LimitedJournal of Biomedicine and Biotechnology1110-72431110-72512011-01-01201110.1155/2011/272806272806Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18Pin Lv0Hongmei Zhu1Hongfang Wang2George Wang3Analytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaAnalytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaAnalytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaAnalytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaHuman papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by them, a 2-plex Luminex-based competitive immunoassay was developed. Unlike the published paper, the no-biotin conjugated neutralizing mAbs spiked normal human serum (NHS) was used for standard curve preparation, while phycoerythrin (PE) was not labeled directly to neutralizing mAbs for signaling. After the coupling optimization of VLPs to microspheres and the neutralizing mAbs biotinylation, the 2-plex standard curve was prepared with good fit and high dynamic range. In addition, no cross-reactivity was also confirmed. The 2-plex Luminex-based immunoassay represents good potential not only for vaccine candidate's evaluation but also for its further clinical use.http://dx.doi.org/10.1155/2011/272806 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pin Lv Hongmei Zhu Hongfang Wang George Wang |
spellingShingle |
Pin Lv Hongmei Zhu Hongfang Wang George Wang Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18 Journal of Biomedicine and Biotechnology |
author_facet |
Pin Lv Hongmei Zhu Hongfang Wang George Wang |
author_sort |
Pin Lv |
title |
Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18 |
title_short |
Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18 |
title_full |
Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18 |
title_fullStr |
Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18 |
title_full_unstemmed |
Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18 |
title_sort |
development of a 2-plex luminex-based competitive immunoassay to quantify neutralizing antibodies induced by virus-like particles for human papillomavirus 16 and 18 |
publisher |
Hindawi Limited |
series |
Journal of Biomedicine and Biotechnology |
issn |
1110-7243 1110-7251 |
publishDate |
2011-01-01 |
description |
Human papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by them, a 2-plex Luminex-based competitive immunoassay was developed. Unlike the published paper, the no-biotin conjugated neutralizing mAbs spiked normal human serum (NHS) was used for standard curve preparation, while phycoerythrin (PE) was not labeled directly to neutralizing mAbs for signaling. After the coupling optimization of VLPs to microspheres and the neutralizing mAbs biotinylation, the 2-plex standard curve was prepared with good fit and high dynamic range. In addition, no cross-reactivity was also confirmed. The 2-plex Luminex-based immunoassay represents good potential not only for vaccine candidate's evaluation but also for its further clinical use. |
url |
http://dx.doi.org/10.1155/2011/272806 |
work_keys_str_mv |
AT pinlv developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18 AT hongmeizhu developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18 AT hongfangwang developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18 AT georgewang developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18 |
_version_ |
1725066521372262400 |